Arbutus Biopharma Stock Forecast, Price & News

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

Is Arbutus Biopharma a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma or view top-rated stocks.

How has Arbutus Biopharma's stock been impacted by COVID-19?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABUS stock has increased by 15.1% and is now trading at $2.97.
View which stocks have been most impacted by COVID-19.

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a drop in short interest in December. As of December 31st, there was short interest totaling 4,550,000 shares, a drop of 43.5% from the December 15th total of 8,060,000 shares. Based on an average trading volume of 9,480,000 shares, the short-interest ratio is currently 0.5 days.
View Arbutus Biopharma's Short Interest.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Arbutus Biopharma.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.24). The biopharmaceutical company earned $3.34 million during the quarter, compared to analyst estimates of $2.36 million. During the same period in the previous year, the firm posted ($0.27) EPS.
View Arbutus Biopharma's earnings history.

What price target have analysts set for ABUS?

5 equities research analysts have issued 12 month price objectives for Arbutus Biopharma's shares. Their forecasts range from $5.00 to $9.00. On average, they expect Arbutus Biopharma's share price to reach $6.90 in the next twelve months. This suggests a possible upside of 132.3% from the stock's current price.
View analysts' price targets for Arbutus Biopharma or view top-rated stocks among Wall Street analysts.

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:

• William H. Collier, President, Chief Executive Officer & Director
• David C. Hastings, Chief Financial & Accounting Officer
• Michael J. Sofia, Chief Scientific Officer
• Elizabeth Howard, Secretary, Chief Compliance Officer & EVP
• Michael J. McElhaugh, Chief Business Officer

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arbutus Biopharma's key competitors?

Some companies that are related to Arbutus Biopharma include Morphic (MORF), Supernus Pharmaceuticals (SUPN), Xenon Pharmaceuticals (XENE), IVERIC bio (ISEE), Zogenix (ZGNX), Erasca (ERAS), Myovant Sciences (MYOV), Bicycle Therapeutics (BCYC), Lyell Immunopharma (LYEL), Amneal Pharmaceuticals (AMRX), Prometheus Biosciences (RXDX), Amarin (AMRN), Nuvation Bio (NUVB), FibroGen (FGEN) and Avid Bioservices (CDMO).
View all of ABUS's competitors.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%).
View institutional ownership trends for Arbutus Biopharma.

Which major investors are buying Arbutus Biopharma stock?

ABUS stock was purchased by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Arbutus Biopharma or or view top insider-buying stocks.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.97.

How much money does Arbutus Biopharma make?

Arbutus Biopharma has a market capitalization of $401.75 million and generates $6.91 million in revenue each year. The biopharmaceutical company earns $-63.74 million in net income (profit) each year or ($0.91) on an earnings per share basis.

How many employees does Arbutus Biopharma have?

Arbutus Biopharma employs 77 workers across the globe.

When was Arbutus Biopharma founded?

Arbutus Biopharma was founded in 1992.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

Where are Arbutus Biopharma's headquarters?

Arbutus Biopharma is headquartered at 701 VETERANS CIRCLE, WARMINSTER PA, 18974.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at [email protected], or via fax at 604-419-3201.